They showed that NSCLC cells with mutant EGFR which accounts for 20% of NSCLC resistance to tyrosine kinase inhibitors (TKIs) had differing responses to EGFR TKI, Osimertinib, dependent on CAF subtype. This evidence concerns the gene EGFR and non-small cell lung carcinoma.